Email Us
Call Us
AUSTIN, Texas – October 21, 2025 – Altogen Labs has published technical documentation for its validated colorectal cancer xenograft models, including a review of xenografts that were used to dissect epigenetic control of tumor growth. Colorectal cancer presents a global health challenge driven by genetic mutations, environmental influences, and microenvironmental interactions, and is frequently diagnosed at… Continue Reading
News
Altogen Labs Expands Preclinical Immunology Capabilities for Vaccine and Immuno-Oncology Research
AUSTIN, Texas – October 19, 2025 – Altogen Labs today detailed its preclinical immunology capabilities supporting vaccine development, cancer immunotherapy, immune-modulating therapeutics, and cell-based treatment programs. The platform combines immunocompetent, immunodeficient, syngeneic, and humanized animal models with immunogenicity assessment, tumor efficacy studies, immune-response profiling, molecular analysis, and in vivo safety evaluation. Selection of an appropriate… Continue Reading
Altogen Labs Metastatic and Orthotopic Lung Cancer Xenograft Models
AUSTIN, Texas – July 29, 2025 – Altogen Labs has published technical documentation for its validated non-small cell lung cancer xenograft models, including subcutaneous, orthotopic, and metastatic configurations for the preclinical evaluation of tumor growth, metastatic spread, and therapeutic efficacy. Metastasis, not the primary tumor, accounts for the majority of lung cancer mortality — yet many… Continue Reading
Altogen Labs ADME and DMPK Capabilities Supporting Accelerated IND Programs
AUSTIN, Texas – July 12, 2025 – Altogen Labs has published detailed documentation of its ADME and DMPK capabilities, giving sponsors a complete view of the pharmacokinetic and metabolic work available alongside the company’s efficacy and safety services. An IND package is only as strong as its weakest component. A compound with compelling xenograft efficacy… Continue Reading
Validated Glioblastoma Xenograft Models
AUSTIN, Texas – April 22, 2025 – Glioblastoma remains among the most therapeutically resistant human cancers, characterized by diffuse invasion, resistance to conventional treatment, and high mortality. Progress depends on models that reproduce those properties rather than models chosen for convenience of growth. Altogen Labs validated glioblastoma models include published documentation that covers cell handling under… Continue Reading
Altogen Labs Offers 14-Week PDX and Chemotherapy Testing Program for Patient-Derived Xenograft Studies
AUSTIN, Texas – February 22, 2025 – Altogen Labs today detailed its 14-week patient-derived xenograft and chemotherapy testing program, a defined-timeline service for sponsors evaluating compounds against tumor material that retains the genetics and histology of the originating patient tumor. Patient-derived xenografts offer the highest translational relevance available in preclinical oncology, but they are also… Continue Reading
Altogen Labs Expands Preclinical Portfolio with CRISPR/Cas9 Gene Editing Services
AUSTIN, Texas – December 9, 2024 – Altogen Labs today confirmed the availability of comprehensive CRISPR/Cas9 gene editing services within its preclinical research portfolio, enabling precise modification of target genes for sponsors investigating gene function and validating therapeutic targets. Service includes gene knockout and knock-in model development for understanding gene function, and CRISPR library screening for… Continue Reading
Preclinical Research with Advanced Oncology Models and Immuno-oncology Services by Altogen Labs
Altogen Labs is a preclinical research organization specializing in the testing and evaluation of novel pharmacological and biological treatments, including novel anticancer therapies, medical compounds, vaccines, cosmetics, and a wide array of natural products and extracts. With a dedicated team of scientists, Altogen Labs provides a comprehensive suite of laboratory services, utilizing the latest technologies… Continue Reading
Dermatology Candidate Evaluated at Altogen Labs Demonstrates Significant Cytokine Inhibition in Eczema Model
AUSTIN, Texas – September 9, 2024 – A preclinical biomarker study performed for Turn Therapeutics has reported significant inhibition of key inflammatory cytokines by the company’s topical atopic dermatitis candidate GX-03, demonstrating Altogen Labs’ capability in immunology and dermatology models beyond its established oncology portfolio. The study evaluated the immunological inhibitory effects of topically applied… Continue Reading
Altogen Labs OECD-Guideline Toxicology Studies
AUSTIN, Texas – August 22, 2024 – Altogen Labs has published list of OECD-guideline toxicology studies, giving sponsors a single reference for the internationally harmonized protocols available at the company’s Austin, Texas facility. The published menu covers acute oral toxicity (OECD 425), acute dermal toxicity (OECD 402), acute inhalation toxicity (OECD 403), acute dermal irritation… Continue Reading